Please login to the form below

Not currently logged in
Email:
Password:

Senior changes for Forest and Amarin

Dr Lawrence S Olanoff is to retire as president of Forest Laboraties, while Joseph S Zakrzewski is to become CEO of Amarin Corporation

Forest Laboratories has announced the retirement of its president and chief operating officer, Dr Lawrence S. Olanoff, effective December 31, while Amarin Corporation has announced that Joseph S Zakrzewski, an experienced biotech executive, has been appointed as its chief executive officer, effective immediately.

Olanoff, who was president of Forest Research Institute before taking his current role, will stay on as a member of the board of directors at Forest and will become senior scientific advisor, spending at least one week a month working at the company, with his primary focus being on drug-development activities.

Howard Solomon, chairman and CEO of Forest, will additionally take on the role of president of the company after Olanoff's retirement.

Separately, at Amarin, Zakrzewski will continue as chairman of the board, a role he has held since January of this year, and will also lead the company as CEO. Earlier in his career, Zakrzewski served as chief operating officer at Reliant Pharmaceuticals in the period leading up to the company's 2007 acquisition by GlaxoSmithKline (GSK). Most recently, he was chief executive officer of Xcellerex, a privately held biotech company.

Zakrzewski succeeds Colin Stewart, who resigned as president and CEO of the company effective November 10 "to address personal matters." Stewart, a former president and CEO of CollaGenex Pharmaceuticals, led Amarin for only a few months before resigning.  Amarin announced his appointment in August of this year.

John F Thero, who has been the company's chief financial officer since late last year, will replace Stewart as president of Amarin.   Prior to joining Amarin, Thero was chief financial officer at ViaCell and Abiomed.

11th November 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics